Researchers have identified a new way to target a previously undruggable form of lung cancer, which has shown promise in ...

Breakthrough research led by scientists in Manchester has identified a new drug combination that could improve outcomes for ...

Breakthrough research led by scientists in Manchester has identified a new drug combination that could improve outcomes for ...

ARTAN Bio, a longevity biotechnology company based in St. Petersburg, Florida, today announced the close of a $1 million seed round led by company co-founder Michael Torres, Ph.D., following his role ...

Two papers present strong evidence that the codon-anticodon interaction is poised on a tipping point so that, given a nudge, the tRNA can insert the wrong amino acid into the growing polypeptide chain ...

Breakthrough research led by scientists in Manchester has identified a new drug combination that could improve outcomes for ...

The Cambridge programme opened with keynote contributions from George Freeman MP, Prof Deborah Prentice, vice-chancellor of ...

Recently published Huntington's Disease Market Insights report includes a comprehensive understanding of current treatment ...

Detailed price information for Dyadic International (DYAI-Q) from The Globe and Mail including charting and trades.

Artan Biotechnologies LLC has closed a $1 million seed round to support progression of the company’s proprietary mutation-specific codon suppression platform toward first-in-human development.

The Huntington's disease market is projected to experience steady growth, supported by progress in precision medicine, rising investments in research and development, and a deeper understanding ...